Biogen Idec   2Q Revenues: $1.7 billion (+21%)   2Q Earnings: $490.7 million (+27%)   YTD Revenues: $3.1 billion (+16%)   YTD Earnings: $917.4 million (+33%)   Comments: Avonex revenues increased 2% to $774 million in the quarter. Tysabri revenues increased 38% to $387 million, primarily due to the acquisition of Elan’s rights, booking 100% of revenues. Tecfidera, a new oral treatment for MS, had revenues of $192 million in the quarter, exceeding already lofty expectations. Rituxan revenues from...